Is VINC or SRNE more profitable?

Sorrento Therapeutics' return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Vincerx Pharma N/A -248.33% -132.73% Sorrento Therapeutics N/A N/A N/A

Do analysts recommend PRPH or VINC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PRPH or VINC more profitable?

Vincerx Pharma has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Vincerx Pharma's return on equity of -248.33% beat ProPhase Labs' return on equity. Company Net Margins Return on Equity Return on Assets ProPhase Labs -825.01% -482.05% -88.90% Vincerx Pharma N/A -248.33% -132.73%

Which has preferable valuation & earnings, AMPE or VINC?

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ampio Pharmaceuticals N/A N/A -$8.63M -$11.01 N/A Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A

Is AMPE or VINC more profitable?

Ampio Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Ampio Pharmaceuticals N/A N/A N/A Vincerx Pharma N/A -248.33% -132.73%

Is VINC or PTPI more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Vincerx Pharma N/A -248.33% -132.73% Petros Pharmaceuticals N/A -78.22% -23.50%

Do analysts recommend CDT or VINC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, CDT or VINC?

Vincerx Pharma is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CDT Equity N/A N/A -$39.22M -$3.35 thousand N/A Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A

Is CDT or VINC more profitable?

CDT Equity's return on equity of -72.25% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -72.25% -55.44% Vincerx Pharma N/A -248.33% -132.73%

Vincerx Pharma (VINC) Competitors

$0.02 0.00 (0.00%)

As of 09/23/2026 09:30 AM Eastern

Compare

VINC vs. SRNE, PRPH, AMPE, PTPI, and CDT

Should you buy Vincerx Pharma stock or one of its competitors? Vincerx Pharma's main competitors and comparable companies include Sorrento Therapeutics (SRNE), ProPhase Labs (PRPH), Ampio Pharmaceuticals (AMPE), Petros Pharmaceuticals (PTPI), and CDT Equity (CDT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Vincerx Pharma compare to Sorrento Therapeutics?

Vincerx Pharma (NASDAQ:VINC) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Vincerx Pharma has higher earnings, but lower revenue than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.17	N/A

Sorrento Therapeutics' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Sorrento Therapeutics	N/A	N/A	N/A

44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company	Overall Sentiment
Vincerx Pharma	Neutral
Sorrento Therapeutics	Neutral

Vincerx Pharma has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.11, indicating that its share price is 89% less volatile than the broader market.

Summary

Vincerx Pharma beats Sorrento Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Vincerx Pharma compare to ProPhase Labs?

ProPhase Labs (NASDAQ:PRPH) and Vincerx Pharma (NASDAQ:VINC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Vincerx Pharma has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Vincerx Pharma's return on equity of -248.33% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Vincerx Pharma	N/A	-248.33%	-132.73%

Vincerx Pharma has lower revenue, but higher earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.03	-$53.36M	-$2.25	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

In the previous week, ProPhase Labs had 2 more articles in the media than Vincerx Pharma. MarketBeat recorded 2 mentions for ProPhase Labs and 0 mentions for Vincerx Pharma. Vincerx Pharma's average media sentiment score of 0.00 beat ProPhase Labs' score of -0.18 indicating that Vincerx Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
ProPhase Labs	Neutral
Vincerx Pharma	Neutral

ProPhase Labs has a beta of 0.06, meaning that its stock price is 94% less volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vincerx Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Vincerx Pharma beats ProPhase Labs on 8 of the 13 factors compared between the two stocks.

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Vincerx Pharma (NASDAQ:VINC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ampio Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Vincerx Pharma	N/A	-248.33%	-132.73%

Ampio Pharmaceuticals has a beta of 5.96, indicating that its share price is 496% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
Vincerx Pharma	Neutral

Summary

Ampio Pharmaceuticals and Vincerx Pharma tied by winning 4 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Vincerx Pharma (NASDAQ:VINC) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Petros Pharmaceuticals has higher revenue and earnings than Vincerx Pharma. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$0.36	N/A

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Vincerx Pharma has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Vincerx Pharma	Neutral
Petros Pharmaceuticals	Neutral

Summary

Petros Pharmaceuticals beats Vincerx Pharma on 6 of the 9 factors compared between the two stocks.

How does Vincerx Pharma compare to CDT Equity?

CDT Equity (NASDAQ:CDT) and Vincerx Pharma (NASDAQ:VINC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

CDT Equity's return on equity of -72.25% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-72.25%	-55.44%
Vincerx Pharma	N/A	-248.33%	-132.73%

3.3% of CDT Equity shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 7.3% of CDT Equity shares are owned by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vincerx Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, CDT Equity had 5 more articles in the media than Vincerx Pharma. MarketBeat recorded 5 mentions for CDT Equity and 0 mentions for Vincerx Pharma. CDT Equity's average media sentiment score of 0.70 beat Vincerx Pharma's score of 0.00 indicating that CDT Equity is being referred to more favorably in the media.

Company	Overall Sentiment
CDT Equity	Positive
Vincerx Pharma	Neutral

CDT Equity has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Vincerx Pharma is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Summary

CDT Equity beats Vincerx Pharma on 8 of the 11 factors compared between the two stocks.

Get Vincerx Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

VINC vs. The Competition

Export

Metric	Vincerx Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$79K	$12.50B	$7.26B	$13.10B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	0.00	792.39	274.69	25.75
Price / Sales	N/A	850.84	679.25	97.61
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	0.00	10.69	10.52	6.34
Net Income	-$40.16M	$2.83B	$3.49B	$360.00M
7 Day Performance	N/A	-0.69%	-1.08%	-0.10%
1 Month Performance	N/A	-1.10%	-3.39%	-3.41%
1 Year Performance	N/A	2.10%	15.08%	5.46%

Vincerx Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VINC Vincerx Pharma	N/A	$0.02 flat	N/A	-60.8%	$79K	N/A	N/A	60
SRNE Sorrento Therapeutics	N/A	$0.00 flat	N/A	-90.0%	$276K	$60.32M	N/A	949
PRPH ProPhase Labs	0.2137 of 5 stars	$0.01 +26.3%	N/A	-99.7%	$226K	$5.06M	N/A	130
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	N/A	$208K	N/A	N/A	6
PTPI Petros Pharmaceuticals	N/A	$0.00 flat	N/A	-84.4%	$125K	$5.11M	N/A	20	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VINC) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vincerx Pharma (VINC) Competitors

VINC vs. SRNE, PRPH, AMPE, PTPI, and CDT

How does Vincerx Pharma compare to Sorrento Therapeutics?

Summary

How does Vincerx Pharma compare to ProPhase Labs?

Summary

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Summary

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Summary

How does Vincerx Pharma compare to CDT Equity?

Summary

New MarketBeat Followers Over Time

VINC vs. The Competition

Vincerx Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vincerx Pharma (VINC) Competitors

VINC vs. SRNE, PRPH, AMPE, PTPI, and CDT

How does Vincerx Pharma compare to Sorrento Therapeutics?

Which has higher valuation & earnings, VINC or SRNE?

Is VINC or SRNE more profitable?

Do institutionals and insiders believe in VINC or SRNE?

Does the media favor VINC or SRNE?

Which has more volatility & risk, VINC or SRNE?

Summary

How does Vincerx Pharma compare to ProPhase Labs?

Do institutionals and insiders hold more shares of PRPH or VINC?

Is PRPH or VINC more profitable?

Which has higher earnings and valuation, PRPH or VINC?

Does the media favor PRPH or VINC?

Which has more risk & volatility, PRPH or VINC?

Do analysts recommend PRPH or VINC?

Summary

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Do insiders & institutionals have more ownership in AMPE or VINC?

Is AMPE or VINC more profitable?

Which has more volatility & risk, AMPE or VINC?

Which has preferable valuation & earnings, AMPE or VINC?

Does the media refer more to AMPE or VINC?

Summary

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Do insiders & institutionals have more ownership in VINC or PTPI?

Which has better earnings and valuation, VINC or PTPI?

Is VINC or PTPI more profitable?

Which has more risk and volatility, VINC or PTPI?

Does the media favor VINC or PTPI?

Summary

How does Vincerx Pharma compare to CDT Equity?

Is CDT or VINC more profitable?

Do institutionals and insiders believe in CDT or VINC?

Do analysts recommend CDT or VINC?

Does the media prefer CDT or VINC?

Which has more volatility & risk, CDT or VINC?

Which has stronger valuation & earnings, CDT or VINC?

Summary

New MarketBeat Followers Over Time

VINC vs. The Competition

Vincerx Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools